A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas
Phase of Trial: Phase II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs Tasquinimod (Primary)
- Indications Fallopian tube cancer; Gastric cancer; Liver cancer; Ovarian cancer; Peritoneal cancer; Renal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms Umbrella
- Sponsors Ipsen
- 10 Aug 2017 Status changed from active, no longer recruiting to completed, based on the results published in the Targeted Oncology.
- 10 Aug 2017 Results published in the Targeted Oncology
- 13 Sep 2016 This trial was completed in Belgium, according to European Clinical Trials Database record.